This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group
by Zacks Equity Research
AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Top Research Reports for AbbVie, Intel & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).
Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%
by Zacks Equity Research
Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates
by Kinjel Shah
FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up
by Zacks Equity Research
Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised
by Zacks Equity Research
Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.
AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform
by Zacks Equity Research
AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.
AbbVie (ABBV) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 0.82% and 1.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More
by Ahan Chakraborty
Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DIV
Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q1 performance will likely reflect declining sales of Humira following the loss of exclusivity. Sales of Rinvoq and Skyrizi are expected to partially offset this fall.
Pharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other Updates
by Kinjel Shah
J&J (JNJ) beats earnings and sales estimates for the first quarter. Merck (MRK) offers to buy Prometheus Biosciences (RXDX).